References
- Shaw ML, Palese P. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. Vol 1. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
- Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med. 2000;51:407–421.
- Wright PF, Neumann G, Kawaoka Y. Fields Virology. Vol 1. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
- Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson MA. Influenza cost and cost-effectiveness studies globally-a review. Vaccine. 2013;31(46):5339–5348.
- Belser JA, Maines TR, Tumpey TM, Katz JM. Influenza A virus transmission: contributing factors and clinical implications. Expert Rev Mol Med. 2010;12:e39.
- Medina RA, García-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol. 2011;9(8):590–603.
- Pizzorno A, Abed Y, Boivin G. Influenza drug resistance. Semin Respir Crit Care Med. 2011;32(4):409–422.
- Dong G, Peng C, Luo J, et al. Adamantane-resistant influenza a viruses in the world (1902–2013): frequency and distribution of M2 gene mutations. PLoS One. 2015;10(3):e0119115.
- Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series. 1999;41:95–98.
- Gubareva LV, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antiviral Res. 2017;146:12–20.
- Gubareva LV, Nedyalkova MS, Novikov DV, Murti KG, Hoffmann E, Hayden FG. A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. J Gen Virol. 2002;83(Pt 11):2683–2692.
- Ramirez-Gonzalez JE, Gonzalez-Duran E, Alcantara-Perez P, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico. Emerg Infect Dis. 2011;17(2):283–286.
- de La Rosa-Zamboni D, Vazquez-Perez JA, Avila-Rios S, et al. Molecular characterization of the predominant influenza A(H1N1)pdm09 virus in Mexico, December 2011-February 2012. PLoS One. 2012;7(11): e50116.
- Téllez-Sosa J, Rodríguez MH, Gómez-Barreto RE, et al. Using high-throughput sequencing to leverage surveillance of genetic diversity and oseltamivir resistance: a pilot study during the 2009 influenza A(H1N1) pandemic. PLoS One. 2013;8(7):e67010.
- Mosqueda-Gomez JL, Belaunzaran-Zamudio PF, Barba A, Cordova-Villalobos JA, Cuellar-Rodriguez JM, Ernesto Macias A. Surveillance of Oseltamivir-Resistant Influenza A(H1N1) pdm09 in Guanajuato State, Mexico from 2009 to 2012. Rev Invest Clin. 2015;67(4):235–239.
- Okomo-Adhiambo M, Fry AM, Su S, et al. Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14. Emerg Infect Dis. 2015;21(1):136–141.
- Souza TM, Resende PC, Fintelman-Rodrigues N. Detection of oseltamivir-resistant pandemic influenza A(H1N1) pdm2009 in Brazil: can community transmission be ruled out? PLoS One. 2013;8(11):e80081.
- Pontoriero A, Avaro M, Benedetti E, et al. Surveillance of antiviral resistance markers in Argentina: detection of E119V neuraminidase mutation in a post-treatment immunocompromised patient. Mem Inst Oswaldo Cruz. 2016;111(12):745–749.
- Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364(9436):759–765.
- Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 2012;206(2):148–157.
- Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284–3292.
- Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs. 2009;69(18):2523–2531.
- Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol. 1988;62(5):1508–1512.
- Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother. 1986;18(Suppl B):19–29.
- Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother. 2005;49(2):556–559.
- Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis. 2006;193(12):1626–1629.
- Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother. 2002;46(12):3809–3816.
- Little K, Leang SK, Butler J, et al. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill. 2015;20(45).
- Mckimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013;7(Suppl 1):25–36.
- Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437(7062):1108.
- Baz M, Abed Y, Mcdonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006;43(12):1555–1561.
- Ison MG. Influenza in hospitalized adults: gaining insight into a significant problem. J Infect Dis. 2009;200(4):485–488.
- Nitsch-Osuch A, Brydak LB. Influenza viruses resistant to neuraminidase inhibitors. Acta Biochim Pol. 2014;61(3):505–508.
- Takayama I, Nakauchi M, Fujisaki S, Odagiri T, Tashiro M, Kageyama T. Rapid detection of the S247N neuraminidase mutation in influenza A(H1N1)pdm09 virus by one-step duplex RT-PCR assay. J Virol Methods. 2013;188(1–2):73–75.
- Yen HL, Hoffmann E, Taylor G, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol. 2006;80(17):8787–8795.
- Zürcher T, Yates PJ, Daly J, et al. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother. 2006;58(4):723–732.
- Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol. 1996;70(3):1818–1827.
- Kamali A, Holodniy M. Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist. 2013;6:187–198.